Hybio Pharmaceutical 관리

관리 기준 확인 3/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Yu Pinxiang

최고 경영자

CN¥1.8m

총 보상

CEO 급여 비율	n/a
CEO 임기	5.5yrs
CEO 소유권	0.06%
경영진 평균 재임 기간	3.1yrs
이사회 평균 재임 기간	4.7yrs

최근 관리 업데이트

Recent updates

Investor Optimism Abounds Hybio Pharmaceutical Co., Ltd. (SZSE:300199) But Growth Is Lacking

Sep 30

Here's Why Hybio Pharmaceutical (SZSE:300199) Can Afford Some Debt

Jul 20

Hybio Pharmaceutical Co., Ltd.'s (SZSE:300199) Price Is Out Of Tune With Revenues

Jun 03

Hybio Pharmaceutical Co., Ltd.'s (SZSE:300199) 27% Share Price Surge Not Quite Adding Up

Feb 29

Is Hybio Pharmaceutical (SZSE:300199) Using Too Much Debt?

Feb 26

CEO

Yu Pinxiang (51 yo)

5.5yrs

테뉴어

CN¥1,842,600

보상

Ms. Pinxiang Yu serves as Director of Hybio Pharmaceutical Co., Ltd. since May 31, 2019 and serves as its Executive President. She served as a Vice President of Production Department at Hybio Pharmaceutica...

리더십 팀

이름	위치	테뉴어	보상	소유권
Yu Pinxiang	Executive President & Director	no data	CN¥1.84m	0.060% CN¥ 6.1m
Honghong Tu	VP, CFO & Accounting Supervisor	3.3yrs	CN¥649.80k	데이터 없음
Di Yang	VP, Secretary & Director	2.8yrs	CN¥781.00k	데이터 없음
Zhaohui Zeng	Vice President	3.3yrs	CN¥1.19m	데이터 없음
Min Zhang	Vice President	2.9yrs	CN¥616.50k	데이터 없음
Heng Quan	Vice President of Human Resource & Administration Department	no data	CN¥840.50k	데이터 없음
Yu Liu	Vice President of Marketing	no data	CN¥398.30k	데이터 없음

3.1yrs

평균 재임 기간

48yo

평균 연령

경험이 풍부한 관리: 300199 의 관리팀은 경험 ( 3.1 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Yu Pinxiang	Executive President & Director	5.5yrs	CN¥1.84m	0.060% CN¥ 6.1m
Di Yang	VP, Secretary & Director	4.6yrs	CN¥781.00k	데이터 없음
Lian Zhong	Independent Director	3.3yrs	CN¥60.00k	데이터 없음
Shaobin Zeng	Non-Independent Director	4.8yrs	CN¥65.70k	2.46% CN¥ 251.5m
Lu Yang	Member of Non-Employee Supervisory Board	2.9yrs	데이터 없음	데이터 없음
Qingyang Li	Chairman of Supervisory Board	5.5yrs	데이터 없음	데이터 없음
Yangming Tang	VP & Director	3.8yrs	CN¥976.90k	데이터 없음
Wenyan Hu	Independent Director	2.9yrs	CN¥120.00k	데이터 없음
Shaoqiang Zeng	Vice Chairman	15yrs	CN¥60.10k	8.15% CN¥ 833.6m
Shaogui Zeng	Chairman	15yrs	CN¥1.12m	12.41% CN¥ 1.3b
Lin Liang	Supervisor	no data	데이터 없음	데이터 없음

4.7yrs

평균 재임 기간

48yo

평균 연령

경험이 풍부한 이사회: 300199 의 이사회는 경험(평균 재직 기간 4.7 년)으로 간주됩니다.

Hybio Pharmaceutical 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Hybio Pharmaceutical Co., Ltd., Annual General Meeting, May 17, 2024

Hybio Pharmaceutical Co., Ltd., Annual General Meeting, May 17, 2024

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

Less than half of directors are independent

Recent updates

Third quarter 2024 earnings released: CN¥0.045 loss per share (vs CN¥0.15 loss in 3Q 2023)

Hybio Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 30, 2024

Investor Optimism Abounds Hybio Pharmaceutical Co., Ltd. (SZSE:300199) But Growth Is Lacking

Second quarter 2024 earnings released: EPS: CN¥0.003 (vs CN¥0.068 loss in 2Q 2023)

Here's Why Hybio Pharmaceutical (SZSE:300199) Can Afford Some Debt

Hybio Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 24, 2024

Hybio Pharmaceutical Co., Ltd.'s (SZSE:300199) Price Is Out Of Tune With Revenues

Hybio Pharmaceutical Co., Ltd., Annual General Meeting, May 17, 2024

First quarter 2024 earnings released: CN¥0.02 loss per share (vs CN¥0.02 profit in 1Q 2023)

Hybio Pharmaceutical Co., Ltd., Annual General Meeting, May 17, 2024

Hybio Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 27, 2024

Hybio Pharmaceutical Co., Ltd.'s (SZSE:300199) 27% Share Price Surge Not Quite Adding Up

Is Hybio Pharmaceutical (SZSE:300199) Using Too Much Debt?

Hybio Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Apr 27, 2024

Third quarter 2023 earnings released: CN¥0.15 loss per share (vs CN¥0.05 loss in 3Q 2022)

Second quarter 2023 earnings released: CN¥0.068 loss per share (vs CN¥0.049 loss in 2Q 2022)

Hybio Pharmaceutical Co., Ltd. to Report First Half, 2023 Results on Aug 15, 2023

First quarter 2023 earnings released: EPS: CN¥0.02 (vs CN¥0.06 loss in 1Q 2022)

High number of new and inexperienced directors

Third quarter 2022 earnings released: CN¥0.05 loss per share (vs CN¥0.096 loss in 3Q 2021)

Second quarter 2022 earnings released: CN¥0.049 loss per share (vs CN¥0.058 loss in 2Q 2021)

Hybio Pharmaceutical Co., Ltd. (SZSE:300199) agreed to acquire 10.81% stake in Hybio Biotechnology (Dali) Co., Ltd. from Dazhong Transportation (Group) Co., Ltd. (SHSE:600611) for CNY 20 million.

First quarter 2022 earnings: EPS and revenues miss analyst expectations

High number of new and inexperienced directors

High number of new and inexperienced directors

Third quarter 2021 earnings released: CN¥0.096 loss per share (vs CN¥0.009 profit in 3Q 2020)

Less than half of directors are independent

First quarter 2021 earnings released: EPS CN¥0.026 (vs CN¥0.025 in 1Q 2020)

Hybio Pharmaceutical Co., Ltd. to Report Fiscal Year 2020 Results on Apr 23, 2021

New 90-day low: CN¥5.60

New 90-day low: CN¥6.66

New 90-day low: CN¥7.17

New 90-day low: CN¥7.43

Third quarter earnings released

Hybio Pharmaceutical Co., Ltd. to Report Q3, 2020 Results on Oct 28, 2020

First half earnings released

New 90-day high - CN¥7.95

Hybio Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 14, 2020

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령